Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma
Hamid Maadi, Mohammad Hasan Soheilifar, Wonshik Choi, et al.
Cancers (2021) Vol. 13, Iss. 14, pp. 3540-3540
Open Access | Times Cited: 121

Showing 1-25 of 121 citing articles:

Revolutionizing cancer treatment: comprehensive insights into immunotherapeutic strategies
Neha R. Raghani, Mehul R. Chorawala, Mayuresh Mahadik, et al.
Medical Oncology (2024) Vol. 41, Iss. 2
Closed Access | Times Cited: 26
Cutting-edge approaches for targeted drug delivery in breast cancer: beyond conventional therapies
Ramesh Chaudhari, Vishva Patel, Ashutosh Kumar
Nanoscale Advances (2024) Vol. 6, Iss. 9, pp. 2270-2286
Open Access | Times Cited: 20
Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges
Man Wang, Fei Yu, Yuan Zhang
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 8
Resistance to Trastuzumab
Sneha Vivekanandhan, Keith L. Knutson
Cancers (2022) Vol. 14, Iss. 20, pp. 5115-5115
Open Access | Times Cited: 55
Recent Progress in Immunotherapy for Gastric Cancer
Jeesun Yoon, Tae‐Yong Kim, Do‐Youn Oh
Journal of the Korean Gastric Cancer Association (2023) Vol. 23, Iss. 1, pp. 207-207
Open Access | Times Cited: 30
Fc-Engineered Therapeutic Antibodies: Recent Advances and Future Directions
Dalia T. Abdeldaim, Katharina Schindowski
Pharmaceutics (2023) Vol. 15, Iss. 10, pp. 2402-2402
Open Access | Times Cited: 28
CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation
Jiří Eitler, Wiebke Rackwitz, Natalie Wotschel, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 2, pp. e008155-e008155
Open Access | Times Cited: 16
Locally misfolded HER2 expressed on cancer cells is a promising target for development of cancer-specific antibodies
Takao Arimori, Emiko Mihara, Hiroyuki Suzuki, et al.
Structure (2024) Vol. 32, Iss. 5, pp. 536-549.e5
Closed Access | Times Cited: 15
A Comprehensive Overview on Chemotherapy-Induced Cardiotoxicity: Insights into the Underlying Inflammatory and Oxidative Mechanisms
András Nagy, Denise Börzsei, Alexandra Hoffmann, et al.
Cardiovascular Drugs and Therapy (2024)
Open Access | Times Cited: 11
Establishment of a Novel Cancer-Specific Anti-HER2 Monoclonal Antibody H2Mab-250/H2CasMab-2 for Breast Cancers
Mika K. Kaneko, Hiroyuki Suzuki, Yukinari Kato
Monoclonal Antibodies in Immunodiagnosis and Immunotherapy (2024) Vol. 43, Iss. 2, pp. 35-43
Open Access | Times Cited: 11
The Predictive and Prognostic Role of RAS–RAF–MEK–ERK Pathway Alterations in Breast Cancer: Revision of the Literature and Comparison with the Analysis of Cancer Genomic Datasets
Andrea Rocca, Luca Braga, Maria Concetta Volpe, et al.
Cancers (2022) Vol. 14, Iss. 21, pp. 5306-5306
Open Access | Times Cited: 29
Aspects of Phage-Based Vaccines for Protein and Epitope Immunization
Marco Palma
Vaccines (2023) Vol. 11, Iss. 2, pp. 436-436
Open Access | Times Cited: 21
Antibody–Drug Conjugates in Breast Cancer: Ascent to Destiny and Beyond—A 2023 Review
Tian Xiao, Sanji Ali, Danilo Giffoni de Mello Morais Mata, et al.
Current Oncology (2023) Vol. 30, Iss. 7, pp. 6447-6461
Open Access | Times Cited: 18
Liquid metal biomaterials: translational medicines, challenges and perspectives
Hanchi Xu, Jincheng Lu, Yikuang Xi, et al.
National Science Review (2023) Vol. 11, Iss. 2
Open Access | Times Cited: 17
Long non-coding RNAs in drug resistance across the top five cancers: Update on their roles and mechanisms
Yue Shi, Joseph Adu‐Amankwaah, Qizhong Zhao, et al.
Heliyon (2024) Vol. 10, Iss. 5, pp. e27207-e27207
Open Access | Times Cited: 8
Heat Shock Proteins, a Double-Edged Sword: Significance in Cancer Progression, Chemotherapy Resistance and Novel Therapeutic Perspectives
Dominika Kunachowicz, Magdalena Król-Kulikowska, Wiktoria Raczycka, et al.
Cancers (2024) Vol. 16, Iss. 8, pp. 1500-1500
Open Access | Times Cited: 8
Safety Profile of the Trastuzumab-Based ADCs: Analysis of Real-World Data Registered in EudraVigilance
Claudiu Morgovan, Carmen Maximiliana Dobrea, Anca Butucă, et al.
Biomedicines (2024) Vol. 12, Iss. 5, pp. 953-953
Open Access | Times Cited: 8
Phase II trial of HER-Vaxx, a B cell peptide-based vaccine, in HER2-overexpressing advanced gastric cancer patients under platinum-based chemotherapy (HERIZON)
Joshua Tobias, Marina Maglakelidze, Zoran Andrić, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 18, pp. 4044-4054
Open Access | Times Cited: 7
Hsa-miR-21-3p associates with breast cancer patient survival and targets genes in tumor suppressive pathways
Arsalan Amirfallah, Hildur Knútsdóttir, Aðalgeir Arason, et al.
PLoS ONE (2021) Vol. 16, Iss. 11, pp. e0260327-e0260327
Open Access | Times Cited: 39
Evaluation of [89Zr]Zr-DFO-2Rs15d Nanobody for Imaging of HER2-Positive Breast Cancer
Maxwell Ducharme, Lucinda Hall, Whitney Eckenroad, et al.
Molecular Pharmaceutics (2023) Vol. 20, Iss. 9, pp. 4629-4639
Closed Access | Times Cited: 15
Targeting ITGβ3 to Overcome Trastuzumab Resistance through Epithelial–Mesenchymal Transition Regulation in HER2-Positive Breast Cancer
Asiye Büşra Boz Er, İdris Er
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 16, pp. 8640-8640
Open Access | Times Cited: 6
HER-2 positive gastric cancer: Current targeted treatments
Rama Rao Malla, Haasita Reddy Nellipudi, Mundla Srilatha, et al.
International Journal of Biological Macromolecules (2024) Vol. 274, pp. 133247-133247
Closed Access | Times Cited: 5
HER2-Displaying M13 Bacteriophages induce Therapeutic Immunity against Breast Cancer
Junbiao Wang, Alessia Lamolinara, Laura Conti, et al.
Cancers (2022) Vol. 14, Iss. 16, pp. 4054-4054
Open Access | Times Cited: 20
Highly Multiplexing, Throughput and Efficient Single‐Cell Protein Analysis with Digital Microfluidics
Linfeng Cai, Li Lin, Shiyan Lin, et al.
Small Methods (2024)
Closed Access | Times Cited: 4
Prognostic Value of the Baseline Systemic Immune-Inflammation Index in HER2-Positive Metastatic Breast Cancer: Exploratory Analysis of Two Prospective Trials
Jian Pang, Nianhua Ding, Xuan Liu, et al.
Annals of Surgical Oncology (2024) Vol. 32, Iss. 2, pp. 750-759
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top